Introduction {#S0001}
============

The prevalence of childhood overweight (OW) or obesity has increased worldwide, and now represents a major public health crisis with economic consequences and substantial associated health care costs.[@CIT0001]--[@CIT0003] Moreover, childhood obesity is associated with an increased incidence of comorbidities such as insulin resistance, diabetes mellitus, hypertension, sleep apnea, and cardiovascular disease,[@CIT0004]--[@CIT0006] which give rise to increases in both direct and indirect costs.[@CIT0007] Recently, the NCD Risk Factor Collaboration pooled and analyzed population-based data concerning worldwide trends in pediatric obesity from 1975 through 2016, and found that increases in the body mass index (BMI) of children and adolescents had plateaued in high-income countries, while some Asian countries continued to have high rates of childhood and adolescent obesity. Moreover, these trends no longer correlated with those of adults.[@CIT0008] For all these reasons, there is an urgent need to avoid obesity during childhood and identify OW and obese (OB) children at an early age, so they can begin an effective intervention and maintain a healthy weight. The adipose tissue of OBchildren and adolescents not only stores lipids, but also releases large amounts of adipocytokines.[@CIT0009] Overproduction of adipocytokines can increase insulin resistance and blood pressure, cause oxidative stress, and disrupt normal lipid metabolism.

Metabolic syndrome (MetS) is defined as a group of risk factors for type II diabetes mellitus and cardiovascular disease, which include hypertension, abdominal obesity, glucose intolerance, and disorders of lipid metabolism. As a result of the ongoing obesity epidemic among adolescents and children, MetS has also become important public health in that population.[@CIT0010],[@CIT0011] Therefore, biomarkers that can predict the risk for developing metabolism syndrome in adolescents or pediatric populations are critical for better management of this syndrome.

Cholinesterase (ChE) belongs to a group of enzymes that hydrolyze acetylcholine and other choline esters. Human tissues have two different types of ChE enzymes:[@CIT0012] acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). AChE is present in the central nervous system and skeletal muscles and located in the erythrocyte membrane, while BChE (also known as pseudocholinesterase) is synthesized in the liver and secreted into plasma. The main function of AChE is to hydrolyze acetylcholine at the cholinergic synapse. The function of BChE is unclear, but it may be involved in the growth or detoxification of body tissues.[@CIT0013],[@CIT0014] The substrate specificity of ChE enzymes is highly dependent on the structure of the acyl binding pocket, as defined by the phenylalanine residue located at the bottom of the ChE catalyst valley.[@CIT0015],[@CIT0016] The physiological function of BChE has remained unclear; however, several studies have suggested that BChE participates in myelin maintenance, cellular adhesion, and neurogenesis, and serves as a scavenger of toxic molecules.[@CIT0017],[@CIT0018] Current studies investigating the activity of BChE in humans have enrolled adult patients with the hepatobiliary disease,[@CIT0019] hyperlipidemia,[@CIT0020] diabetes,[@CIT0021] or cardiovascular disease.[@CIT0022] However, few studies have investigated changes that occur in BChE activity in OB adults or those with MetS.[@CIT0023]

Although several recent studies have reported increased levels of BChE in the plasma of individuals with abdominal obesity[@CIT0023] and MetS,[@CIT0024] less studies have investigated the relationship between obesity in a general adolescent population and plasma BChE concentrations. Moreover, it remains uncertain whether improved BChE levels would be beneficial to adolescents with MetS; however, that topic has recently received increased attention. While high levels of BChE have been associated with obesity in a variety of populations, this association has not been confirmed in Chinese adolescents' populations, and is the primary aim of this study. We also assessed the relationship between BChE concentrations and several components of MetS.

Material and methods {#S0002}
====================

Study design {#S0002-S2001}
------------

This study was conducted in the city of Shenyang, China, and individuals attending state-funded or private primary and middle schools in traditional urban districts of Shenyang were eligible for inclusion. Our investigation used screening data obtained from a [H]{.ul}uanggu District [M]{.ul}iddle and [P]{.ul}rimary [S]{.ul}chool Student [P]{.ul}hysical Fitness [M]{.ul}onitoring (HMPSPM) database for the years 2017--2018. The database was created to help investigate the health outcomes, weight status, and growth status of primary and middle-school children and adolescents in northeast China, as previously described.[@CIT0025] In this research, a cross-sectional school-based survey of 13--19-year-old adolescents (n=1559) was conducted in five middle schools in the Huanggu District in Shenyang City, China, from September 2017 to April 2018. Anthropometric measurements and blood sample data were collected. All eligible participants and their parent(s) signed an Informed Consent agreement prior to participating in the study. The study protocol was approved by the Ethics Committee of the Institute of Health Science (Ethics Approval No. \[2017\] 055), China Medical University (CMU), and all study procedures were performed in accordance with the Declaration of Helsinki.

School and participant recruitment {#S0002-S2002}
----------------------------------

The city of Shenyang is administratively divided into three rural districts and ten urban districts, and this study was conducted only in the Huanggu urban district, and only schools located in the Huanggu District of Shenyang City were selected for participation. Each participating school had a different schedule for administering physical examinations; therefore, this study used a two-phase physical examination and blood sample collection approach. In the Phase (I), four middle schools were randomly selected from the Huanggu District in Shenyang City during September or October of 2017. In the Phase (II), April 2018, another middle school was selected from the list of all primary schools in the Huanggu District. The selected schools were invited to participate in our study via a written invitation from the Primary and Secondary School Healthy Care Center of Huanggu District and followed by telephone calls. Visits were made to explain the purpose of the study, confirm participation, and obtain a signed written Informed Consent document from each school's principal. Student birth dates were obtained from the school's registration form in order to confirm the adolescent's age. If selected schools enroll less than 100 students were excluded in this study. Students who were older than 18 years, who had a severe systemic disease or intellectual impairment were also excluded in this research from participation.

Study population {#S0002-S2003}
----------------

From September 2017 to April 2018, our study initially enrolled 1,559 Chinese adolescent students in grades 7--12 from five public or private middle schools in Shenyang, China. After anthropometry measurements and blood sample analyses were completed, a total of 1,236 adolescent students (age 13--18 years) remained eligible to participate. A flowchart showing the participant selection process is provided in [Figure 1](#F0001){ref-type="fig"}.Figure 1The northeast of Chinese adolescents participant flow.

Anthropometric measurements {#S0002-S2004}
---------------------------

A single researcher performed all anthropometric measurements in accordance with World Health Organization standards. Student heights were measured to the nearest 0.1 cm using a portable stadiometer (SECA 213, Hamburg, Germany), and weights were measured in kilograms using a body fat analyzer (TANITA DC430MA, Tokyo, Japan). BMI was calculated as weight in kilograms divided by height in meters squared (kg/m^2^). Z-scores were assigned to represent the standard deviation of each individual's BMI from the average value for age and gender-matched population according to Chinese reference values for different ages and genders. Hip and waist circumference were measured by established techniques,[@CIT0026] and waist-to-height and waist-to-hip ratios (WHtR and WHR) were calculated as waist circumference (cm) divided by height (cm) and hip circumference (cm), respectively. The body adiposity index (BAI)[@CIT0027] was calculated as BAI =(hip circumference \[cm\]/height \[m\]^1.5^) −18. Blood pressure was measured with an Omron i-C10 blood pressure monitor (Omron Healthcare Co., Ltd, Kyoto, Japan), and arterial hypertension was defined according to existing recommendations[@CIT0028]

Blood sample collection {#S0002-S2005}
-----------------------

Venipuncture was performed with the written informed consent of each participant and their parents, who were aware of the intended use of the samples. The Ethics Committee of the Institute of Health Science, China Medical University (CMU) approved the venous blood collection protocol, which was performed in accordance with the Declaration of Helsinki. Venipuncture was performed after a 12-hr fast, and specimens were collected in EDTA plastic tubes (BD Vacutainer® lavender, 5.0 mL) or anticoagulant and silica/gel plastic tubes (SST BD Vacutainer® gold, 5.0 mL). Plasma was obtained by centrifugation and could be stored for up to six months at −80°C for further analysis.

Laboratory examinations {#S0002-S2006}
-----------------------

All adolescent blood tests were conducted by the Department of Clinical Laboratory, Shengjing Hospital of CMU. The blood test results for each student were provided to the corresponding middle school. When abnormal results were obtained, the student was notified and encouraged to have a second blood test performed after a 1-month interval or visit an outpatient clinic.

Hepatic panel. ALT, AST, ALP, and GGT levels were measured by using an International Federation of Clinical Chemistry method (Abbott Laboratories, North Chicago, IL, USA). Plasma BChE was measured according to the recommendation by DGKC which is a kinetic method and Cholinesterase Assay Kit (Beijing Strong Biotechnologies, Inc, China), which uses Colorimetic Butrylthiocholine as a substrate[@CIT0029] Total bile acid was measured by the butyryl glucosinolates choline substrate method and enzymatic cycling method, respectively (Beijing Strong Biotechnologies, Inc, China). Total protein, albumin (Alb), total bilirubin (TBil), and conjugated bilirubin (CB) concentrations were determined by the biuret method, the BCG method, and the vanadic acid oxidation method, respectively (FUJIFILM Wako Pure Chemical industries Ltd, Japan). Pre-albumin (PA1) was measured by immunoturbidimetric method (Prealbumin FS, ERM®-DA470k/IFCC, DiaSys Diagnostic Systems GmbH, Germany).

Lipid panel. The selective solubilization method (Low-density lipid cholesterol test Kit or Determiner L HDL, Kyowa Medex, Tokyo) was used to directly analyze the plasma levels of low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C), and enzymatic methods were used to measure total cholesterol (TC) and triglyceride (TG) levels. ApoA1 and ApoB levels were measured using immunoturbidimetric method (Kits for BioMajesty® JCA-BM6010/C, DiaSys Diagnostic Systems GmbH, Germany). The lipid profiles were generated by an automatic biochemistry analyzer (ARCHIRECT ci16200, Abbott Laboratories, USA).

Definition of clinical variables {#S0002-S2007}
--------------------------------

### Definition of adolescent OW and obesity {#S0002-S2007-S3001}

OW and obesity were defined by BMI in accordance with recommendations made by the Working Group on Obesity in China (WGOC)[@CIT0030] as: ≥28, OB; 24.0--27.9, OW; 18.5--23.9, normal weight (NW); \<18.5, underweight (UW). According to the 2005 WGOC standard, a BMI of 24 was the cut-off point for OB vs OW.[@CIT0031]

### Definition of MetS {#S0002-S2007-S3002}

MetS was diagnosed in accordance with the International Diabetes Federation (IDF) consensus report on MetS in adolescents population.[@CIT0032] In children aged from 6 to 10 years, MetS cannot be diagnosed, but further measurements should be made if there is a family history of MetS or type 2 diabetes mellitus (T2DM). In this research, a school-based survey of 13--19-year-old adolescents was conducted. Therefore, MetS is diagnosed when central obesity plus any two of the other four factors: (1) a TG level ≥150 mg/dL; (2) an HDL-C level \<40 mg/dL for boys of all ages and girls aged \<16 years, and an HDL-C level \<50 mg/dL for girls aged ≥16 years; (3) A systolic blood pressure (BPS) ≥130 mmHg or diastolic blood pressure (BPD) ≥85 mmHg; (4) a fast plasma glucose (FPG) level more than 5.6 mmol/L or known T2DM. Central obesity is defined as a waist circumference at or above the 90th percentile for age and gender in children under the age of 16, and as a waist circumference ≥90 cm (male) or ≥80 cm (female) after age 16.

### Definition of cholinesterase (BChE) stratum {#S0002-S2007-S3003}

The upper and lower strata of BChE levels were defined according to the cut-off values for the 75th percentile,[@CIT0033] which in the present study were 8481.0U/L for girls and 9083.3U/L for boys.

Statistical analysis {#S0002-S2008}
--------------------

SPSS 22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. And a *P*-value \<0.05 was considered statistically significant.

Because of the non-Gaussian data distribution in this study, data for continuous variables are expressed as medians with upper or lower quartiles. Kruskal--Wallis one-way analysis of variance by rank test and the non-parametric Mann--Whitney test were used to analyze differences among more than two groups and differences between two groups, respectively. Categorical data are expressed as numbers with percentages. The chi-square test was used to examine the differences between the two groups in terms of biochemical and clinical parameters.

Multiple logistic regression analyses were performed by first carrying out multiple linear and logistic regression analyses adjusted for confounding factors, including gender and age, to examine the association between BChE and adolescent weight status. Standardized regression coefficients and odds ratios (ORs) with 95% confident intervals (95%CIs) are presented with adjustments made for potential confounding factors. Additionally, receiver operating characteristic (ROC) curves of plasma BChE for the diagnosis of adolescent's metabolism syndrome were used to evaluate the clinical utility of performing BChE concentration in predicting MetS in adolescents. Areas under the ROC curve (AUCs) were calculated for both girls and boys.

Results {#S0003}
=======

Baseline characteristics {#S0003-S2001}
------------------------

[Table 1](#T0003){ref-type="table"} shows the baseline characteristics of the study participants. The participants were classified according to weight status as OB (n=194, 85 girls and 109 boys); OW ( n=188, 91 girls and 97 boys); NW (n=732, 379 girls and 353 boys); or UW (n=122, 60 girls and 62 boys). In the whole cohorts, the prevalence of upper strata BChE levels was markedly higher in the OB group than in the other groups. The prevalence of MetS in the OB group was 30.4% and, in OW group adolescents, it was 5.3%. The direct associations of anthropometry, blood biochemical parameters, and BChE concentrations with gender are presented in [Table S1](#ST0001). In the girls' cohorts, the prevalence of upper strata BChE levels was markedly higher in the OB group than in the other groups as well as the boys' cohorts. Table 1Characteristics of the study populationParameterUW, median (lower; upper quartiles)NW, median (lower; upper quartiles)OW, median (lower; upper quartiles)OB, median (lower; upper quartiles)*P*-valueBody height (cm)1.70 (1.64; 1.73)1.67 (1.61; 1.73)1.66 (1.60; 1.73)1.70 (1.64; 1.77)EBody weight (kg)44.50 (41.70; 48.28)55.80 (50.70; 61.01)70.30 (65.05; 76.30)91.10 (82.30; 102.65)A-FWaist circumference (cm)63.50 (60; 67.25)69.00 (65.00; 73.00)80 (75; 84)93.5 (87.38; 100)A-FHip circumference (cm)84 (82.75; 86.25)91 (88; 94)100 (97; 103)110 (107; 115)A-FBMI (kg m-2)15.74 (15.36; 16.2)20.22 (18.74; 21.56)25.48 (24.58; 26.75)31.37 (29.49; 33.85)A-FBMI z-score−1.43 (−1.51; −1.33)−0.49 (−0.8; −0.21)0.62 (0.43; 0.88)1.85 (1.46; 2.37)A-FBody weight z-score−1.2 (−1.38; −0.96)−0.48 (−0.8; −0.14)0.46 (0.12; 0.84)1.8 (1.23; 2.54)A-FWaist circumference z-score−0.97 (−1.29; −0.63)−0.46 (−0.83; −0.1)0.55 (0.09; 0.91)1.79 (1.23; 2.39)A-FHip circumference z-score−1.23 (−1.37; −0.97)−0.44 (−0.78; −0.09)0.59 (0.25; 0.93)1.72 (1.38; 2.29)A-FWHtR0.38 (0.36; 0.39)0.41 (0.39; 0.43)0.48 (0.46; 0.5)0.55 (0.52; 0.58)A-FWHR0.75 (0.71; 0.81)0.76 (0.73; 0.78)0.8 (0.77; 0.83)0.85 (0.81; 0.89)B-FBPS (mm Hg)116.5 (109.75; 121.25)115 (107; 123)122 (113; 133)131.5 (124; 144.25)B-FBPD (mmHg)70 (60.5; 78.25)65 (60; 70)67 (61; 73)71.5 (65; 77.25)D, EPulse rate85 (76.5; 96.25)85 (75; 92)85 (77; 92.5)86 (76.75; 96)NSTP (g/L)78 (76.58; 83.05)79.9 (77; 82.9)79.9 (76.9; 82.75)80 (77.2; 83.03)NSAlbumin, Alb (g/L)50.65 (48.78; 53.65)50.8 (48.9; 52.7)50.3 (48.65; 52.3)49.7 (47.7; 52.03)C, EALT (U/L)9.5 (7.75; 11)10 (8; 13)13 (9; 19)25 (14; 39.25)A-FAST (U/L)14 (13; 15.25)15 (13; 17)16 (13; 19)19 (15; 25)C, E, FALP (U/L)103.5 (70; 159.25)93 (76; 121)93 (75.5; 120.5)101 (81.75; 126.75)NSGGT (U/L)15 (11.75; 16)15 (12; 19)18 (14; 26)26 (19; 34.25)B-FBChE (U/L)7,351 (6661.25; 7891.75)7,709 (7014.5; 8,478)8,350 (7,610; 9217.5)9294.5 (8,463; 10,127.5)B-FPA1 (g/L)0.24 (0.21; 0.27)0.25 (0.22; 0.28)0.25 (0.22; 0.29)0.27 (0.23; 0.29)C,EBilT (mmol/L)16.8 (13.73; 22.9)13.3 (9.8; 17.3)12.8 (9.8; 16.25)12.25 (9.3; 16.23)NSCB (mmol/L)6.3 (5.2; 8.25)5.3 (3.8; 6.9)4.8 (3.5; 6.6)4.65 (3.5; 6.23)NSUCB (mmol/L)10.7 (7.93; 14.3)8.1 (5.9; 10.55)7.7 (6; 10)7.55 (5.65; 10.1)NSTBA (mmol/L)2.8 (2; 4.38)2.4 (1.4; 3.6)2 (1.15; 3.2)2 (1.3; 3.13)B, DFPG (mmol/L)4.3 (3.87; 4.55)4.28 (4; 4.56)4.28 (3.99; 4.58)4.31 (4; 4.64)NSTG (mmol/L)0.67 (0.53; 0.88)0.71 (0.53; 0.96)0.81 (0.58; 1.07)1.04 (0.75; 1.44)C, E, FTC (mmol/L)3.9 (3.43; 4.32)3.84 (3.41; 4.3)3.95 (3.46; 4.45)4.25 (3.82; 4.7)C, E, FHDL-C (mmol/L)1.42 (1.12; 1.73)1.34 (1.17; 1.54)1.24 (1.1; 1.47)1.13 (0.99; 1.26)B-ELDL-C (mmol/L)1.94 (1.69; 2.53)2.05 (1.71; 2.43)2.19 (1.81; 2.55)2.54 (2.16; 2.85)B, C, E, FApoA1 (g/L)1.39 (1.21; 1.49)1.33 (1.22; 1.46)1.26 (1.16; 1.4)1.24 (1.13; 1.34)B-EApoB (g/L)0.58 (0.49; 0.7)0.6 (0.52; 0.7)0.66 (0.56; 0.75)0.76 (0.64; 0.86)B-FMetS (n/N,%)0/122 (0.0%)2/732 (0.3%)10/188 (5.3%)59/194 (30.4%)B-F[^1][^2]

Association of each lipid biomarker with an adolescent's weight status {#S0003-S2002}
----------------------------------------------------------------------

Direct associations between the levels of various plasma lipid biomarkers the BMI values of adolescents are shown in [Table 2](#T0004){ref-type="table"}. The levels of circulating TG, TC, LDL-C, and apolipoprotein B (ApoB) were all positively associated with the BMI values of adolescents (all *P*-values\<0.001). A multiple logistic regression analysis showed that when compared with the NW groups, all six classical indices (ie, TG, TC, HDL-C, LDL-C, ApoA1, and ApoB) were predictive for both OB and OW+OB, and that HDL-C, LDL-C, ApoA1, and ApoB were predictive for OW ([Table 3](#T0005){ref-type="table"}).Table 2Associations of hepatic panels and lipid biomarkers with adolescents weight status according to gender using linear regression analysisTotalBoysGirlsCoefficients*P*-valueCoefficients*P*-valueCoefficients*P*-valueBPS0.1220.0000.1010.0000.1200.000BPD−0.0390.025−0.0590.156−0.0790.080Pulse−0.0390.196−0.0580.137−0.0730.072TP (g/L)−0.0840.0040.0030.954−0.2650.000albumin, Alb (g/L)−0.1310.000−0.3270.000−0.0610.048ALT (U/L)0.0540.0000.0590.0000.0590.005AST (U/L)−0.0250.000−0.0070.8860.0590.000ALP (U/L)0.0530.000−0.0200.000−0.0280.000GGT (U/L)0.0470.0110.0640.0060.0450.417BChE (U/L)0.1110.0000.1010.0000.0540.006PA1 (g/L)−0.0410.155−0.0310.430−0.0180.641BilT (mmol/L)−0.0180.5510.0210.5820.0180.656CB (mmol/L)−0.0070.8110.0360.3460.0330.413UCB (mmol/L)−0.0290.312−0.0010.9830.0080.850TBA (mmol/L)−0.0480.075−0.0380.302−0.0730.064FPG (mmol/L)0.0050.8700.0300.421−0.0060.882TG (mmol/L)0.188\<0.0010.168\<0.0010.213\<0.001TC (mmol/L)0.151\<0.0010.1380.0030.1240.006HDL-C (mmol/L)−0.142\<0.001−0.0670.149−0.268\<0.001LDL-C (mmol/L)0.201\<0.0010.188\<0.0010.192\<0.001ApoA1 (g/L)−0.0320.340−0.0360.237−0.162\<0.001ApoB (g/L)0.255\<0.0010.250\<0.0010.232\<0.001[^3][^4] Table 3Associations of hepatic panels and lipid biomarkers with adolescent weight status using logistic regression analysisParametersNWUW*P*-valueOW*P*-valueOB*P*-valueOW+OB*P*-valueBPS (mmHg)1 reference0.98 (0.96; 1.00)0.0351.05 (1.03; 1.07)0.0001.09 (1.07; 1.11)0.0001.07 (1.06; 1.09)0.000BPD (mmHg)1 reference1.03 (1.00; 1.06)0.0481.05 (1.02; 1.07)0.0001.06 (1.04; 1.09)0.0001.06 (1.04; 1.08)0.000Pulse1 reference1.01 (0.99; 1.03)0.4791.02 (0.99; 1.03)0.0671.01 (0.99; 1.02)0.3531.01 (1.00; 1.03)0.069TP (g/L)1 reference1.01 (0.96; 1.06)0.8031.00 (0.96; 1.04)0.9811.00 (0.96; 1.04)0.9431.00 (0.97; 1.03)0.973Albumin, Alb (g/L)1 reference1.01 (0.97; 1.05)0.5690.93 (0.85; 1.01)0.0580.88 (0.81; 0.95)0.0010.90 (0.85; 0.96)0.001ALT (U/L)1 reference0.90 (0.84; 0.97)0.0041.06 (1.04; 1.09)0.0001.13 (1.10; 1.06)0.0001.10 (1.07; 1.12)0.000AST (U/L)1 reference0.99 (0.92; 1.06)0.7111.04 (0.99; 1.09)0.1501.04 (1.08; 1.19)0.0001.09 (1.05; 1.13)0.000ALP (U/L)1 reference1.00 (1.00; 1.01)0.1441.00 (0.99; 1.01)0.1841.00 (0.99; 1.01)0.1681.00 (0.99; 1.01)0.075GGT (U/L)1 reference0.94 (0.89; 0.99)0.0221.07 (1.04; 1.10)0.0001.15 (1.11; 1.18)0.0001.11 (1.08; 1.14)0.000BChE (U/L)1 reference0.78 (0.63; 0.96)0.0221.31 (1.10; 1.55)0.0022.44 (1.97; 3.02)0.0001.76 (1.52; 2.05)0.000PA1 (g/L)1 reference0.02 (0.01; 10.72)0.2302.45 (0.22; 27.83)0.47012.73 (0.35; 466.56)0.166180.44 (0.59; 576.92)0.097BilT (mmol/L)1 reference1.02 (0.99; 1.06)0.1751.00 (0.97; 1.03)0.9570.99 (0.96; 1.02)0.3960.99 (0.97; 1.11)0.603CB (mmol/L)1 reference1.07 (0.97; 1.02)0.1580.99 (0.91; 1.07)0.7640.94 (0.86; 1.03)0.1700.97 (0.90; 1.03)0.286UCB (mmol/L)1 reference1.02 (0.98; 1.07)0.2961.00 (0.96; 1.04)0.9190.99 (0.94; 1.03)0.5400.99 (0.96; 1.03)0.718TBA (mmol/L)1 reference1.05 (0.95; 1.16)0.3320.88 (0.77; 0.99)0.0360.88 (0.77; 0.99)0.0410.88 (0.80; 0.96)0.007FPG (mmol/L)1 reference0.73 (0.41; 1.28)0.2660.89 (0.56; 1.41)0.6150.94 (0.59; 1.51)0.8090.91 (0.63; 1.31)0.598TG (mmol/L)1 reference0.98 (0.49; 1.95)0.9521.15 (0.67; 1.97)0.6234.49 (2.79; 7.23)0.0002.51 (1.70; 3.72)0.000TC (mmol/L)1 reference0.88 (0.59; 1.31)0.5291.15 (0.85; 1.55)0.6382.09 (1.54; 2.84)0.0001.52 (1.20; 1.92)0.000HDL-C (mmol/L)1 reference1.83 (0.73; 4.57)0.1950.23 (0.10; 0.52)0.0000.07 (0.03; 0.17)0.0000.14 (0.07; 0.27)0.000LDL-C (mmol/L)1 reference0.74 (0.46; 1.2)0.2251.64 (1.15; 2.35)0.0073.04 (2.08; 4.43)0.0002.21 (1.65; 2.96)0.000ApoA1 (g/L)1 reference1.79 (0.45; 7.14)0.4100.09 (0.03; 0.33)0.0000.20 (0.06; 0.69)0.0110.15 (0.06; 0.40)0.000ApoB (g/L)1 reference0.48 (0.08; 3.02)0.4376.09 (1.83; 26.5)0.004304.49 (64.8; 1430.81)0.00047.79 (15.14; 150.87)0.000[^5]

Association of each liver enzyme biomarker with an adolescent's weight status {#S0003-S2003}
-----------------------------------------------------------------------------

The associations between liver enzyme biomarker levels and the BMI values of adolescents are shown in [Table 2](#T0004){ref-type="table"}. Interestingly, serum or plasma ALT, AST, ALP, GGT, and BChE levels were positively associated with the BMI values of adolescents (ALT: *P*\<0.001, AST: *P*\<0.001, ALP: *P*\<0.001, GGT: *P*=0.011 and BChE: *P*\<0.001). A multiple logistic regression analysis showed that plasma ALT, AST, GGT, and BChE levels were positively associated with both the OB group and OW+OB group when compared with the NW group ([Table 3](#T0005){ref-type="table"}). For example, the adjusted ORs of BChE increased from 1.31 (95%CI: 1.10--1.55, *p*=0.002) at an OW status to 2.44 (95%CI: 1.97--3.02, *P*\<0.001) at an OB status.

The stratum of BChE according to weight categories and gender {#S0003-S2004}
-------------------------------------------------------------

The prevalence of upper stratum BChE levels was 17.8% in the UW group, 16.0% in the NW group, 31.1% in the OW group, and 57.9% in the OB group ([Table 4](#T0006){ref-type="table"}). In the OW group, boys had a significantly higher prevalence of upper stratum BChE levels (38.2% vs 23.6% in girls; *P*\<0.001). However, there were no significant gender differences in the OB groups. The mean values of most anthropometric parameters, such as BMI, BMI z-score, waist and hip circumference, WHR, WHtR, some of transaminase categories, and several traditional lipid biomarkers were significantly higher in the upper stratum of the BChE levels than in the lower stratum ([Table S2](#ST0002)). Moreover, a multiple logistic regression analysis revealed that the plasma TG, TC, LDL-C, and ApoB levels were positively associated with the upper stratum of BChE levels when compared with the lower stratum (OR=3.76, 2.19, 2.84, 69.07, respectively, all *P*-values\<0.001), and this was true in both the boys and girls cohorts. Furthermore, plasma ApoA1 and HDL-C levels showed negative associations with the upper stratum of the BChE levels when compared with the lower stratum ([Table 5](#T0007){ref-type="table"}).Table 4The low or upper level of plasma BChE in the study population according to weight categories and genderWeight statusGenderBChE lowBChE uppern (%)Chi-square testUWBoys54 (86.5%)8 (13.5%)62 (100%)Chi-square test: 1.086; *P*=0.149Girls47 (77.8%)13 (22.2%)60 (100%)Total100 (82.2%)22 (17.8%)122 (100%)NWBoys309 (87.4%)44 (12.6%)353 (100%)Chi-square test: 5.791; *P*=0.008Girls306 (80.7%)73 (19.3%)379 (100%)Total615 (84.0%)117 (16.0%)732 (100%)OWBoys60 (61.8%)37 (38.2%)97 (100%)Chi-square test: 3.630; *P*=0.028Girls69 (76.4%)22 (23.6%)91 (100%)Total129 (68.9%)59 (31.1%)188 (100%)OBBoys43 (39.1%)66 (60.9%)109 (100%)Chi-square test: 0.568; *P*=0.226Girls39 (46.0%)46 (54.0%)85 (100%)Total82 (42.1%)112 (57.9%)194 (100%)OW+OBBoys103 (49.8%)103 (50.2%)206 (100%)Chi-square test: 4.508; *P*=0.017Girls108 (61.7%)68 (38.3%)176 (100%)Total211 (55.3%)171 (44.7%)382 (100%)[^6] Table 5Associations of parameters with the upper stratum of the BChE levels when compared with the lower stratumALLBoysGirlsBChE lowerBChE upper*P*-valueBChE upper*P*-valueBChE upper*P*-valueBody height (cm)1 Reference1.21 (0.16; 9.04)0.8517.49 (0.2; 284.93)0.2780.19 (0; 10.43)0.417Body weight (kg)1 Reference1.04 (1.03; 1.05)0.0001.06 (1.04; 1.07)0.0001.04 (1.02; 1.06)0.000Waist circumference (cm)1 Reference1.07 (1.05; 1.09)0.0001.09 (1.07; 1.12)0.0001.06 (1.03; 1.08)0.000Hip circumference (cm)1 Reference1.09 (1.07; 1.11)0.0001.12 (1.08; 1.15)0.0001.06 (1.03; 1.09)0.000BMI (kg m^--2^)1 Reference1.16 (1.12; 1.21)0.0001.20 (1.14; 1.27)0.0001.13 (1.07; 1.19)0.000BMI z-score1 Reference2.09 (1.75; 2.49)0.0002.43 (1.88; 3.14)0.0001.79 (1.39; 2.30)0.000Body weight z-score1 Reference1.93 (1.62; 2.29)0.0002.35 (1.83; 3.02)0.0001.74 (1.32; 2.30)0.000Waist circumference z-score1 Reference2.1 (1.76; 2.51)0.0002.64 (2.04; 3.43)0.0001.81 (1.38; 2.37)0.000Hip circumference z-score1 Reference2.1 (1.75; 2.51)0.0002.60 (1.99; 3.38)0.0001.68 (1.30; 2.18)0.000WHtR1 Reference4.51 (2.48; 9.06)0.0001.25 (1.07; 1.54)0.0008.38 (2.06; 11.40)0.000WHR1 Reference16.90 (10.06; 35.22)0.00033.68 (25.12; 43.65)0.00049.12 (37.5; 66.32)0.001BPS (mm Hg)1 Reference1.03 (1.02; 1.05)0.0001.04 (1.03; 1.06)0.0001.04 (1.02; 1.06)0.000BPD (mmHg)1 Reference1.03 (1.01; 1.05)0.0011.03 (1.00; 1.06)0.0321.04 (1.01; 1.07)0.008Pulse1 Reference1.02 (1.00; 1.03)0.0111.01 (0.99; 1.03)0.2021.02 (1.00; 1.04)0.017TP (g/L)1 Reference1.08 (1.04; 1.13)0.0001.08 (1.02; 1.14)0.0121.09 (1.03; 1.15)0.002albumin, Alb (g/L)1 Reference1.01 (0.98; 1.05)0.4991.09 (0.99; 1.20)0.0661.00 (0.96; 1.04)0.967ALT (U/L)1 Reference1.06 (1.04; 1.07)0.0001.06 (1.04; 1.08)0.0001.06 (1.03; 1.10)0.000AST (U/L)1 Reference1.02 (0.99; 1.03)0.0791.10 (1.05; 1.16)0.0001.00 (0.99; 1.02)0.778ALP (U/L)1 Reference1.00 (0.99; 1;01)0.7731.00 (0.99; 1.00)0.4691.00 (0.99; 1.01)0.565GGT (U/L)1 Reference1.07 (1.05; 1.09)0.0001.09 (1.06; 1.12)0.0001.07 (1.04; 1.11)0.000PA1 (g/L)1 Reference32.39 (0.85; 1236.03)0.06128.19 (3.54; 254.37)0.0002.25 (0.18; 28.22)0.531BilT (mmol/L)1 Reference0.98 (0.95; 1.01)0.1060.98 (0.95; 1.01)0.2140.97 (0.92; 1.02)0.196CB (mmol/L)1 Reference0.91 (0.84; 0.97)0.0070.88 (0.79; 0.98)0.0140.89 (0.77; 1.02)0.082UCB (mmol/L)1 Reference0.98 (0.95; 1.02)0.3090.98 (0.94; 1.03)0.4860.97 (0.90; 1.04)0.350TBA (mmol/L)1 Reference0.99 (0.91; 1.07)0.7571.05 (0.95; 1.16)0.3720.90 (0.78; 1.04)0.140FPG (mmol/L)1 Reference1.35 (0.92; 1.99)0.1261.14 (0.65; 2.02)0.6451.61 (0.93; 2.79)0.091TG(mmol/L)1 Reference3.76 (2.50; 5.68)0.0004.28 (2.42; 7.56)0.0003.30 (1.82; 5.99)0.000TC (mmol/L)1 Reference2.19 (1.70; 2.82)0.0002.65 (1.82; 3.86)0.0001.91 (1.35; 2.71)0.000HDL-C (mmol/L)1 Reference0.18 (0.09; 0.35)0.0000.12 (0.04; 0.33)0.0000.21 (0.08; 0.55)0.001LDL-C (mmol/L)1 Reference2.84 (2.09; 3.86)0.0003.72 (2.35; 5.89)0.0002.27 (1.50; 3.43)0.000ApoA1 (g/L)1 Reference0.32 (0.12; 0.83)0.0190.36 (0.09; 1.49)0.1600.26 (0.07; 1.00)0.050ApoB (g/L)1 Reference69.07 (21.78; 219.04)0.000110.41 (20.49; 594.89)0.00047.04 (9.47; 233.71)0.000[^7]

The stratum of BChE and prevalence of MetS {#S0003-S2005}
------------------------------------------

The prevalence of MetS and its components is shown in [Table 6](#T0008){ref-type="table"}. MetS was defined according to the IDF definition, and its overall prevalence was 6.1% in boys and 5.3% in girls. Regarding the components of MetS, elevated BP was more common in boys and low HDL-C levels were more common in girls.Table 6Prevalence of metabolic syndrome and its componentsBoysGirls*P*-valueBoysGirlsBChE lowBChE upper*P*-valueBChE lowBChE upper*P*-valueMtS6.1 (0.9)5.3 (0.9)0.3280.4 (0.3)15.4 (2.8)\<0.0012.2 (0.6)14.3 (2.8)\<0.001Abdominal obesity (%)25.1 (1.7)23.8 (1.7)0.30913.9 (1.6)57.3 (4.0)\<0.00118.3 (3.6)38.5 (3.9)\<0.001Elevated BP (%)30.9 (1.8)9.2 (1.1)\<0.00124.1 (2.0)53.4 (4.0)\<0.0014.8 (1.0)22.5 (3.3)\<0.001High FPG (%)1.6 (0.5)1.9 (0.6)0.4911.5 (0.6)1.1 (0.8)0.6431.1 (0.5)4.4 (1.6)0.069High TG (%)5.3 (0.9)3.8 (0.8)0.1162.2 (0.7)15.7 (3.0)\<0.00012.2 (0.7)8.8 (2.3)0.009Low HDL-C (%)18.9 (1.6)38.8 (2.0)\<0.00115.3 (1.7)30.3 (3.7)0.00235.5 (2.2)50.5 (4.0)0.008[^8]

MetS and most of its components were more prevalent among the upper stratum than the lower stratum BChE levels. When adjusted age variable, [Figure 2](#F0002){ref-type="fig"} explores the mean individual BChE levels based on the number of MetS components. The mean age-adjusted BChE level increased with the presence of MetS in both boys and girls (*P*-value for trend \<0.001).Figure 2Age-adjusted mean plasma BChE levels by the number of components of metabolic syndrome (error bars represent standard error of the mean). Black columns represent data for boys, and shaded columns represent data for girls.

ROC curves for plasma BChE concentrations in subjects with MetS are shown in [Figure 3](#F0003){ref-type="fig"}. After adjusting for age, the AUC was 0.80 (95%CI: 0.70--0.90, *P*\<0.001) in girls and 0.89 (95%CI: 0.82--0.95, *P*\<0.001) in boys.Figure 3Receiver operating characteristic curves of plasma BChE level for metabolic syndrome in girls and boys.

When compared with adolescents in the lower stratum of BChE concentration, that in the upper stratum of BChE levels were at a dramatically higher risk of suffering from MetS and its components ([Table 7](#T0009){ref-type="table"}), with the exception of boys in the high fast plasma glucose cohorts. After adjusting for age, the multivariate-adjusted OR for MetS in the upper stratum of BChE levels of the male cohorts was 8.73 (95%CI: 3.49--21.84). Moreover, subjects in the upper stratum of BChE levels were also at a higher risk for MetS and its components, with the exception of girls who had high FPG levels and elevated BP.Table 7Multivariate-adjusted odds ratios and 95% confidence intervals for metabolic syndrome and its components according to BChE level in boys and girls Chinese adolescentBoysGirlsBChE lowBChE upper*P*-valueBChE lowBChE upper*P*-valueMtS1 Reference8.73 (3.49--21.84)\<0.0011 Reference1.71 (1.35--21.70)\<0.001Abdominal obesity (%)1 Reference8.89 (4.61--13.50)\<0.0011 Reference1.67 (1.29--2.16)\<0.001Elevated BP (%)1 Reference3.32 (2.02--5.45)\<0.0011 Reference2.08 (0.99--4.38)0.053High TG (%)1 Reference8.09 (3.01--21.76)\<0.0011 Reference4.29 (1.45--12.72)0.009High FPG (%)1 Reference0.747 (0.08--6.77)0.7961 Reference4.14 (0.91--18.85)0.066Low HDL-C (%)1 Reference2.32(1.33--4.05)0.0031 Reference1.86 (1.15--2.99)0.012

Discussion {#S0004}
==========

In the present study, significantly higher BChE concentrations were observed in OB adolescent subjects when compared with UW, NW, and OW adolescents, respectively. Some cross-sectional studies have shown a significant association of plasma BChE levels and BMI, dyslipidemia, and MetS in cohorts of adult subjects.[@CIT0034] Moreover, the mean BChE concentration in OB subjects tends to be higher than that in non-OB subjects.[@CIT0035] The present study investigating the correlation between plasma BChE levels and adolescent weight status, BMI, lipid profiles, and liver enzymes or hepatic panels were similar to those reported from previous studies conducted with adults[@CIT0023] However, ours is the first large-scale study to show that plasma BChE concentrations are associated with BMI and MetS components, and were increased above their normal levels in an OB Chinese adolescent population.

BChE and adolescent obesity {#S0004-S2001}
---------------------------

We initially observed that OB adolescents have a high level of plasma BChE activity, whereas normal subjects have low levels of plasma BChE activity. Our multiple logistic regression analysis showed that the BChE concentration was association with being OW or OB rather than of NW. Several studies have observed associations between plasma BChE concentration and plasma triacylglycerol and cholesterol levels in adults.[@CIT0020],[@CIT0023],[@CIT0036] Furthermore, numerous studies have shown positive correlations between BChE concentration and the levels of lipoprotein, eg, very low-density lipoprotein, and LDL-C, and a weak negative correlation between BChE activity and HDL-C levels.[@CIT0020],[@CIT0036],[@CIT0037] In this study, we confirmed these results in an adolescent population, and found that triacylglycerol, cholesterol, LDL-C, and ApoB levels were positively associated with the upper stratum of BChE levels compared with the lower stratum. Lipoproteins have a phosphorylcholine group that can interact with BChE, and this suggests that they may play a role in lipoprotein metabolism.[@CIT0038] Furthermore, other studies have shown that BChE plays a role in lipid metabolism, either directly or via a synergistic action with cholesterol esterase.[@CIT0039],[@CIT0040]

Several animal studies have shown a statistically significant increase in plasma ChE levels during fattening in pigs (the same breed), which might be due to an adaptative increase of the hepatic synthesis of BChE in response to the increased lipid metabolism.[@CIT0041] Another study in mice revealed an increase in the plasma ChE levels of lean mice on a high carbohydrate diet, which suggested a marked reduction (40%) in BChE activity occurred in the liver of genetically diabetic mice when starved for 24 hrs.[@CIT0042] These findings reveal that an increase in plasma ChE levels is a result of obesity or weight gain, rather than a cause.

BChE and MetS in adolescents {#S0004-S2002}
----------------------------

The functional significance of elevated plasma BChE level in individuals with risk factors for metabolism syndrome is also unclear. Several mechanisms could explain this association. Previous study suggested that plasma BChE levels were correlated with waist circumference and components of visceral fatarea.[@CIT0043] Our present study in adolescents found an association between BChE levels and waist circumference, waist-to-hip ratio, and waist-to-height ratio. Increased visceral fat has been confirmed to be associated with future insulin resistance,[@CIT0044] and this association may partially be as a result of insulin resistance resulting from plasma BChE and visceral adiposity. Simultaneously, an increase in the BChE level could indicate an increase in fat infiltration in the liver, and a higher BChE level has been frequently observed in non-alcoholic fatty liver disease[@CIT0045] Non-alcoholic fatty liver disease is increasingly being regarded as a manifestation of MetS and insulin resistance. Another mechanism for these associations may be inflammation. BChE catalyzes the hydrolysis of acetylcholine, succinylcholine, and butyrylcholine.[@CIT0018] As widely reported, the acetylcholine plays an anti-inflammatory activity role physiological status.[@CIT0018] Elevated plasma BChE levels could lead to reduced acetylcholine levels and low-grade inflammation,[@CIT0046] which may partially be involved in the pathogenesis of MetS associated with plasma BChE, because inflammation is likely to induce insulin resistance.[@CIT0047] Thirdly, a mechanism for these associations may be polymorphisms. The polymorphisms of BuChE have been reported to be associated with BMI, obesity, and hypertriglyceridemia in adolescents. A southern Brazil study has suggested that individuals with innately high BChE activity tend to be thinner, and that people who gain weight have increased levels of BChE synthesis. They suggested that 1914G allele showed a significantly higher frequency in the OB group. Furthermore, when compared with 1914A carriers, the carriers of 1914G BChE gene allele display lower mean BChE activity. Simultaneously, higher mean BMI and TG levels were found in the 1914G carriers when compared with the 1914A homozygotes.[@CIT0048] Therefore, it is possible that 1914G BChE gene allele can be interfering in lipolysis, hyperglycemia, gluconeogenesis, and body fat distribution. This lower activity may cause an imbalance in lipid metabolism, which could lead to a lower ability to maintain metabolic homeostasis. The previous study[@CIT0049] revealed that plasma BChE plays a role in the cleavage of ghrelin. Ghrelin, the "hunger hormone", is a peptide hormone produced by the stomach and involved in regulating the distribution, rate of use of energy, induction of adiposity, the stimulation of growth hormone release, and weight gain. Desacyl ghrelin is produced as a result of ghrelin cleavage, and it plays a role of cell proliferation and stimulates adipogenesis. This function indicates an important role for butylcholinesterase (BChE) in the development and progression of both obesity and MetS.[@CIT0049]

Above all, the association between plasma BChE activity and TC, LDL-cholesterol, and TGs strongly suggests its value as a risk marker for obesity and MetS in adolescents. As BChE activity is easily measured for a low cost, its predictive value when used with other markers for assessing MetS risk should not be overlooked.[@CIT0034]

Our present study has several limitations that should be mentioned. First, due to the cross-sectional nature of the study, temporal relations between BChE and the outcomes of adolescent obesity cannot be discerned, and it remains unclear whether a higher BChE level is a direct risk factor for adolescent obesity and metabolism syndrome or simply an epiphenomenon. Therefore, it is necessary to perform a prospective study to confirm the causal relationship between plasma BChE levels and obesity and MetS among adolescents. Secondly, enrolled adolescent students belonged to a single ethnic cohort and they were registered in the same city. Even though they may apply to other east Asian adolescents, our conclusion may not be representative of the general adolescents population. Thirdly, we could not ignore the role that the physiological effect of puberty on insulin resistance. Some researchers have shown that adolescents population suffer from transient insulin resistance during puberty.[@CIT0050] Finally, detailed information about polymorphisms of BChE was not available. Polymorphisms of BChE have been reported to be associated with obesity in adolescents. However, the corresponding data on the pubertal stage of our research participants were not included in this HMPSPM dataset. Here, the pubertal stage of the enrolled adolescents was not directly considered in our study. Even though, we performed analysis by involved age and gender as a confounding variable in the multiple logistic regression analysis to minimize the influence of this limitation. Even with these potential limitations, our study results are of good general applicability because nationally representative cohorts of children and adolescents from China were used in the study. In addition, the reliability of our findings is strengthened by a large number of normal-weight participants.

Conclusion {#S0005}
==========

In the present study, we investigated plasma BChE as a hepatic metabolism biomarker that can predict OW, obesity, and MetS in Chinese adolescents. Our results showed: (1) a positive association between upper strata plasma BChE levels with adolescents OW and an even greater association with obesity. (2) In the OW cohort, boys had a significantly higher prevalence of upper stratum BChE levels, but there were no significant gender-related differences in the OB cohorts. (3) Plasma TG, TC, LDL-C, and ApoB levels were positively associated with the upper stratum of BChE levels when compared with the lower stratum, and this was true for both boys and girls. (4) Plasma BChE levels were positively associated with MetS and its components. These findings contribute to our understanding of the association of plasma BChE concentration and MetS or its components in Chinese adolescent's cohorts. Larger prospective studies are needed to confirm our results.
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Table S1Characteristics of study population according to gender.ParameterUW, median (lower; upper quartiles)NW, median (lower; upper quartiles)OW, median (lower; upper quartiles)OB, median (lower; upper quartiles)*P*-value (men)*P*-value (women)MenWomenMenWomenMenWomenMenWomenBody height (cm)1.73 (1.7; 1.74)1.63 (1.58; 1.65)1.72 (1.68; 1.75)1.61 (1.57; 1.65)1.71 (1.67; 1.75)1.62 (1.58; 1.65)1.76 (1.71; 1.79)1.62 (1.56; 1.67)E, FNSBody weight (kg)49.97 (47.8; 51.6)44.73 (42.17; 47.1)59.9 (56.12; 63.85)53.05 (49.53; 56.4)73.35 (68.8; 79.1)66.05 (61.97; 71.2)93.75 (87.44; 105.82)81.07 (73.72; 88.1)A-FA-EWaist circumference (cm)66 (63; 68)63 (61; 65)72 (69; 75)67 (65; 70)80 (77; 85)77 (74; 80)95 (91; 102.75)87 (83; 92)A-FA-FHip circumference (cm)86 (83; 89)86 (85; 89)92 (89; 95)92 (88; 94)99 (97; 102)99 (97; 101)110 (107; 113.75)107 (104; 110.25)A-FA-FBMI (kg m^−2^)16.86 (16.49; 17.08)17.26 (16.46; 17.7)20.17 (19.28; 21.61)20.37 (19.37; 21.67)25.19 (24.36; 25.66)25.11 (24.59; 26.13)30.22 (28.54; 34)30.63 (28.89; 33.19)A-FA-FBMI z-score−1.17 (−1.25; −1.12)−1.09 (−1.25; −1)−0.49 (−0.67; −0.19)−0.44 (−0.65; −0.18)0.55 (0.38; 0.65)0.53 (0.43; 0.75)1.59 (1.24; 2.37)1.68 (1.32; 2.2)A-FA-FBody weight z-score−0.83 (−0.97; −0.73)−1.17 (−1.33; −1.02)−0.2 (−0.44; 0.05)−0.64 (−0.86; −0.42)0.66 (0.37; 1.03)0.2 (−0.07; 0.52)1.97 (1.56; 2.74)1.15 (0.69; 1.6)A-FA-EWaist circumference z-score−0.76 (−1.03; −0.57)−1.03 (−1.22; −0.85)−0.21 (−0.48; 0.07)−0.67 (−0.85; −0.39)0.53 (0.25; 0.99)0.25 (−0.02; 0.53)1.91 (1.54; 2.62)1.17 (0.8; 1.63)A-FA-FHip circumference z-score−1.04 (−1.38; −0.69)−1.04 (−1.15; −0.69)−0.34 (−0.69; 0)−0.34 (−0.81; −0.11)0.46 (0.23; 0.81)0.46 (0.23; 0.69)1.73 (1.38; 2.16)1.38 (1.04; 1.76)A-FA-FWHtR0.38 (0.37; 0.39)0.39 (0.37; 0.4)0.42 (0.4; 0.44)0.42 (0.4; 0.44)0.47 (0.44; 0.49)0.47 (0.46; 0.49)0.54 (0.52; 0.58)0.54 (0.51; 0.57)A-FA-FWHR0.77 (0.73; 0.81)0.73 (0.69; 0.75)0.78 (0.76; 0.81)0.74 (0.72; 0.76)0.81 (0.79; 0.84)0.78 (0.75; 0.8)0.87 (0.84; 0.91)0.82 (0.78; 0.85)B-FB-FBPS (mm Hg)119 (112; 124)108 (101; 114)121 (114; 128.5)110 (104; 117)128 (118; 135)120 (109; 125)138 (129.25; 147)124.5 (116.5; 130.25)B-FB-EBPD (mmHg)69 (61; 72)65 (61; 72)65 (60; 69)65 (59; 70)67 (62; 73)68 (64; 75)70.5 (62.25; 76.75)67.5 (62; 76.25)ED, EPulse84 (75; 93)86 (76; 98)79 (70; 89.5)85 (77; 93)82 (71; 91)91 (82; 98)81 (75; 92.75)86 (77; 96.75)NSDTP (g/L)78.5 (75.2; 82.7)79.1 (77.1; 82.8)79.4 (76.85; 82.55)80.1 (77; 82.6)79.8 (76.4; 84.3)79.2 (76.5; 82.8)80.35 (77.18; 83.28)78.2 (76.38; 82.33)NSNSalbumin, Alb (g/L)51.1 (49.9; 52.5)50.3 (48.9; 53)51.5 (50.05; 53.3)49.8 (48.3; 52.1)51.2 (49.4; 53.5)48.9 (47.4; 50.9)51.5 (49.13; 52.88)47.95 (46.18; 50.03)NSB, C, EALT (U/L)10 (8; 12)8 (6; 10)11 (9; 15)9 (7; 12)16 (12; 27)10 (7; 14)26 (20; 40.5)12 (10; 25)B-FB, C, EAST (U/L)16 (15; 18)15 (13; 16)16 (14; 19)15 (13; 17)17 (16; 20)14 (12; 16)20 (16; 25)15 (12; 20)C, ENSALP (U/L)126 (102; 177)87 (72; 109)115 (94.5; 153)78 (66; 90)111 (95; 143)76 (69; 90)106.5 (86.75; 129)79.5 (72.5; 94)CNSGGT (U/L)17 (14; 20)12 (10; 15)18 (15; 21)13 (11; 16)22 (18; 31)16 (13; 19)29 (23.25; 36)19 (14.75; 26.25)B-FB-FBChE (U/L)7,258 (6,834; 8,399)7,397 (6,353; 8,480)7,957 (7,267; 8649.5)7,392 (6,782; 8,232)8,563 (7,616; 9,514)7,747 (7,185; 8,442)9325.5 (8,719; 10,341.5)8639.5 (7,554; 9,389)B-FC, E, FPA1 (g/L)0.25 (0.23; 0.28)0.24 (0.2; 0.25)0.27 (0.24; 0.29)0.23 (0.2; 0.25)0.28 (0.25; 0.3)0.24 (0.21; 0.26)0.28 (0.26; 0.3)0.24 (0.21; 0.27)B, C, ENSBilT (mmol/L)19.1 (12.5; 24.1)10.8 (8.4; 15.4)16 (12.95; 19.4)11.4 (8.8; 14.5)15.6 (11.3; 19.2)11.3 (8.3; 13.5)15.6 (11.28; 20.9)10.25 (7.8; 12.23)NSNSCB (mmol/L)7.9 (5.4; 9.5)4.2 (3; 5.9)6.3 (5.2; 7.8)4.3 (3.2; 5.5)5.9 (4.8; 8.1)3.9 (3.1; 5.1)5.85 (4.43; 7.58)3.7 (3.1; 4.7)NSNSUCB (mmol/L)10.8 (8.8; 15.5)7 (5.3; 9.9)9.6 (7.65; 11.75)7.1 (5.4; 9.2)8.8 (6.8; 11.8)7.1 (5.4; 9)9.4 (6.48; 12.88)6.4 (4.8; 7.6)NSNSTBA (mmol/L)2.2 (1.5; 3.4)2.6 (2; 5)2.3 (1.35; 3.5)2.5 (1.5; 3.8)1.7 (1.1; 3)2 (1.1; 3.2)1.9 (1.25; 3.1)2 (1.38; 3.05)NSNSFPG (mmol/L)4.16 (3.99; 4.47)4.27 (4.07; 4.49)4.16 (3.93; 4.45)4.29 (4.06; 4.63)4.13 (3.8; 4.38)4.3 (4.11; 4.64)4.23 (3.96; 4.63)4.36 (4.01; 4.59)NSNSTG (mmol/L)0.79 (0.58; 1.04)0.77 (0.59; 0.93)0.66 (0.51; 0.95)0.73 (0.57; 1.01)0.7 (0.52; 0.95)0.79 (0.56; 1.01)1.01 (0.69; 1.42)0.97 (0.77; 1.39)E, FC, E, FTC (mmol/L)3.71 (3.2; 4.1)3.88 (3.45; 4.3)3.61 (3.34; 4.09)3.91 (3.54; 4.34)3.7 (3.25; 4.15)4.06 (3.49; 4.58)4.08 (3.74; 4.57)4.21 (3.75; 4.67)C, E, FC, EHDL-C (mmol/L)1.26 (1.17; 1.63)1.43 (1.3; 1.62)1.28 (1.13; 1.45)1.41 (1.23; 1.59)1.17 (1.01; 1.34)1.28 (1.17; 1.52)1.13 (0.98; 1.27)1.2 (1.07; 1.34)B-EC, ELDL-C (mmol/L)1.84 (1.64; 2.25)2.07 (1.58; 2.45)1.94 (1.66; 2.27)2.1 (1.77; 2.45)2.07 (1.69; 2.39)2.33 (1.91; 2.78)2.47 (2.11; 2.76)2.46 (2.05; 2.82)C, E, FB, C, EApoA1 (g/L)1.32 (1.24; 1.42)1.43 (1.27; 1.55)1.28 (1.19; 1.41)1.35 (1.24; 1.48)1.22 (1.09; 1.33)1.29 (1.16; 1.42)1.24 (1.15; 1.34)1.28 (1.21; 1.34)B, DC, EApoB (g/L)0.56 (0.5; 0.67)0.62 (0.51; 0.69)0.59 (0.5; 0.69)0.62 (0.54; 0.7)0.62 (0.52; 0.71)0.7 (0.6; 0.8)0.74 (0.66; 0.83)0.74 (0.64; 0.86)C, E, FC-E Table S2Characteristics of study population according to the the plasma BChE low or upper level in the whole cohort, in girls and in boysBChE lowerBChE upper*P*-valueBChE lowerBChE upper*P*-valueBChE lowerBChE upper*P*-valueBody height (cm)1.67 (1.61; 1.73)1.66 (1.61; 1.74)0.9881.67 (1.61; 1.74)1.66 (1.61; 1.75)0.9881.67 (1.61; 1.75)1.66 (1.61; 1.76)0.988Body weight (kg)58.2 (51.59; 65.78)69.38 (56.3; 84.68)0.00058.2 (51.59; 65.79)69.38 (56.3; 84.69)0.00058.2 (51.59; 65.80)69.38 (56.3; 84.70)0.000Waist circumference (cm)70 (66; 76)79 (70; 90)0.00071 (66; 76)80 (70; 90)0.00072 (66; 76)81 (70; 90)0.000Hip circumference (cm)92 (89; 97)98 (92; 108)0.00093 (89; 97)99 (92; 108)0.00094 (89; 97)100 (92; 108)0.000BMI (kg m-2)20.72 (18.94; 23.4)24.8 (20.57; 29.13)0.00020.72 (18.94; 23.5)24.8 (20.57; 29.14)0.00020.72 (18.94; 23.6)24.8 (20.57; 29.15)0.000BMI z-score−0.37 (−0.74; 0.18)0.47 (−0.4; 1.36)0.000−0.37 (−0.74; 0.19)0.47 (−0.4; 1.37)0.000−0.37 (−0.74; 0.20)0.47 (−0.4; 1.38)0.000Body weight z-score−0.31 (−0.73; 0.18)0.41 (−0.43; 1.39)0.000−0.31 (−0.73; 0.19)0.41 (−0.43; 1.40)0.000−0.31 (−0.73; 0.20)0.41 (−0.43; 1.41)0.000Waist circumference z-score−0.39 (−0.76; 0.16)0.44 (−0.39; 1.45)0.000−0.39 (−0.76; 0.17)0.44 (−0.39; 1.46)0.000−0.39 (−0.76; 0.18)0.44 (−0.39; 1.47)0.000Hip circumference z-score−0.34 (−0.69; 0.23)0.35 (−0.34; 1.5)0.000−0.34 (−0.69; 0.24)0.35 (−0.34; 1.6)0.000−0.34 (−0.69; 0.25)0.35 (−0.34; 1.7)0.000WHtR0.42 (0.4; 0.46)0.47 (0.42; 0.53)0.0000.42 (0.4; 0.47)0.47 (0.42; 0.54)0.0000.42 (0.4; 0.48)0.47 (0.42; 0.55)0.000WHR0.77 (0.74; 0.8)0.8 (0.75; 0.85)0.0000.77 (0.74; 0.9)0.8 (0.75; 0.86)0.0000.77 (0.74; 0.10)0.8 (0.75; 0.87)0.000BPS (mm Hg)116 (108; 126)123 (114; 134)0.000117 (108; 126)124 (114; 134)0.000118 (108; 126)125 (114; 134)0.000BPD (mmHg)66 (60; 71)69 (62; 75)0.00067 (60; 71)70 (62; 75)0.00068 (60; 71)71 (62; 75)0.000Pulse83 (74; 91.25)86.5 (76; 96)0.00784 (74; 91.25)86.5 (76; 97)0.00785 (74; 91.25)86.5 (76; 98)0.007TP (g/L)79.1 (76.7; 82.1)80.95 (77.6; 84.08)0.00079.1 (76.7; 82.2)80.95 (77.6; 84.09)0.00079.1 (76.7; 82.3)80.95 (77.6; 84.10)0.000albumin, Alb (g/L)50.3 (48.6; 52.3)51.15 (49.03; 52.9)0.00950.3 (48.6; 52.4)51.15 (49.03; 52.10)0.00950.3 (48.6; 52.5)51.15 (49.03; 52.11)0.009ALT (U/L)10 (8; 14)14 (9.25; 26.75)0.00011 (8; 14)15 (9.25; 26.75)0.00012 (8; 14)16 (9.25; 26.75)0.000AST (U/L)16 (13; 18)17 (14; 21)0.00017 (13; 18)18 (14; 21)0.00018 (13; 18)19 (14; 21)0.000ALP (U/L)92 (75; 118)94.5 (78.25; 122.75)0.26593 (75; 118)94.5 (78.25; 122.76)0.26594 (75; 118)94.5 (78.25; 122.77)0.265GGT (U/L)16 (13; 19)20 (15; 29)0.00017 (13; 19)21 (15; 29)0.00018 (13; 19)22 (15; 29)0.000PA1 (g/L)0.25 (0.22; 0.28)0.27 (0.23; 0.29)0.0000.25 (0.22; 0.29)0.27 (0.23; 0.30)0.0000.25 (0.22; 0.30)0.27 (0.23; 0.31)0.000BilT (mmol/L)13.7 (10.1; 17.7)12.35 (9.55; 16)0.02213.7 (10.1; 17.8)12.35 (9.55; 17)0.02213.7 (10.1; 17.9)12.35 (9.55; 18)0.022CB (mmol/L)5.4 (3.9; 7.2)4.7 (3.5; 6.1)0.0025.4 (3.9; 7.3)4.7 (3.5; 6.2)0.0025.4 (3.9; 7.4)4.7 (3.5; 6.3)0.002UCB (mmol/L)8.3 (6.1; 10.7)7.6 (5.8; 10.05)0.0698.3 (6.1; 10.8)7.6 (5.8; 10.06)0.0698.3 (6.1; 10.9)7.6 (5.8; 10.07)0.069TBA (mmol/L)2.3 (1.5; 3.6)2 (1.2; 3.2)0.0282.3 (1.5; 3.7)3 (1.2; 3.2)0.0282.3 (1.5; 3.8)4 (1.2; 3.2)0.028FPG (mmol/L)4.24 (3.97; 4.51)4.3 (4.01; 4.61)0.0894.24 (3.97; 4.52)4.3 (4.01; 4.62)0.0894.24 (3.97; 4.53)4.3 (4.01; 4.63)0.089TG (mmol/L)0.73 (0.53; 0.98)0.9 (0.64; 1.25)0.0000.73 (0.53; 0.99)0.9 (0.64; 1.26)0.0000.73 (0.53; 0.100)0.9 (0.64; 1.27)0.000TC(mmol/L)3.78 (3.39; 4.23)4.13 (3.74; 4.7)0.0003.78 (3.39; 4.24)4.13 (3.74; 4.8)0.0003.78 (3.39; 4.25)4.13 (3.74; 4.9)0.000HDL-C (mmol/L)1.32 (1.15; 1.53)1.22 (1.08; 1.39)0.0001.32 (1.15; 1.54)1.22 (1.08; 1.40)0.0001.32 (1.15; 1.55)1.22 (1.08; 1.41)0.000LDL-C (mmol/L)2 (1.71; 2.38)2.38 (2.05; 2.82)0.0003 (1.71; 2.38)2.38 (2.05; 2.83)0.0004 (1.71; 2.38)2.38 (2.05; 2.84)0.000ApoA1 (g/L)1.31 (1.21; 1.44)1.29 (1.18; 1.4)0.0471.31 (1.21; 1.45)1.29 (1.18; 1.5)0.0471.31 (1.21; 1.46)1.29 (1.18; 1.6)0.047ApoB (g/L)0.6 (0.52; 0.7)0.7 (0.61; 0.83)0.0000.6 (0.52; 0.8)0.7 (0.61; 0.84)0.0000.6 (0.52; 0.9)0.7 (0.61; 0.85)0.000

[^1]: **Note:** \**P*=Kruskal--Wallis multiple-comparison Z value test. *P*-values \<0.05 were considered statistically significant: A=UW vs NW, B=UW vs OW, C=UW vs OB, D=NW vs OW, E=NW vs OB, F=OW vs OB.

[^2]: **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group; BMI, body mass index; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; BPS, systolic blood pressure; BPD, diastolic blood pressure; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; PA1, pre-albumin; BilT, total bilirubin; CB, conjugated bilirubin; UCB, un-conjugated bilirubin; TBA, total bile acid; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ApoA1, apolipoprotein A1; AopB, apolipoprotein B.

[^3]: **Note:** \**P*=Kruskal--Wallis multiple-comparison Z value test. *P*-values \<0.05 were considered statistically significant: A=UW vs NW, B=UW vs OW, C=UW vs OB, D=NW vs OW, E=NW vs OB, F=OW vs OB.

[^4]: **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group; BMI, body mass index; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; BPS, systolic blood pressure; BPD, diastolic blood pressure; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidas; PA1, pre-albumin; BilT, total bilirubin; CB, conjugated bilirubin; UCB, un-conjugated bilirubin; TBA, total bile acid; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ApoA1, apolipoprotein A1; AopB, apolipoprotein B.

[^5]: **Note:** Multiple logistic regression analyses were performed and ORs (95% CIs) were showed with adjustment for age and gender.

    **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group; BMI, body mass index; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; BPS, systolic blood pressure; BPD, diastolic blood pressure; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; PA1, pre-albumin; BilT, total bilirubin; CB, conjugated bilirubin; UCB, un-conjugated bilirubin; TBA, total bile acid; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ApoA1, apolipoprotein A1; AopB, apolipoprotein B.

[^6]: **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group.

[^7]: **Note:** multiple logistic regression analyses were performed and ORs (95% CIs) were showed with adjustment for age and gender.

    **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group; BMI, body mass index; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; BPS, systolic blood pressure; BPD, diastolic blood pressure; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidas; PA1, pre-albumin; BilT, total bilirubin; CB, conjugated bilirubin; UCB, un-conjugated bilirubin; TBA, total bile acid; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ApoA1, apolipoprotein A1; AopB, apolipoprotein B.

[^8]: **Note:** Data are presented as percentage (standard error). *P*-values were obtained by using weighted Chi-square test.

    **Abbreviations:** UW, underweight group; NW, normal weight group; OW, overweight group; OB, obese group; BMI, body mass index; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; BPS, systolic blood pressure; BPD, diastolic blood pressure; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; PA1, pre-albumin; BilT, total bilirubin; CB, conjugated bilirubin; UCB, un-conjugated bilirubin; TBA, total bile acid; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ApoA1, apolipoprotein A1; AopB, apolipoprotein B.
